Advertisement

Search Results

Advertisement



Your search for Matthew S matches 1076 pages

Showing 901 - 950


leukemia

No Difference in Event-Free Survival With Stem Cell Transplantation Using Matched Unrelated vs Sibling Donor Grafts in Children With ALL

In a European trial (Berlin-Frankfurt-Muenster study group trial ALL-SCT-BFM 2003) reported in the Journal of Clinical Oncology, Peters et al found no difference in event-free survival with stem cell transplantation using matched unrelated vs sibling donors in pediatric patients with high-risk...

solid tumors
issues in oncology

Comprehensive Genomic Profiling Shows Distribution of Targetable Alterations in Carcinomas of Unknown Primary Site

In a study reported in JAMA Oncology, Ross et al found potentially targetable genomic alterations in most carcinomas of unknown primary site using comprehensive genomic profiling. Adenocarcinomas of unknown primary site frequently harbored receptor tyrosine kinase/Ras/MAPK pathway alterations....

leukemia

Factors in Ibrutinib Discontinuation in Patients With Chronic Lymphocytic Leukemia

In a single-center study reported in JAMA Oncology, Maddocks et al found that Richter’s transformation accounted for early progression-related discontinuation of ibrutinib (Imbruvica) in patients with chronic lymphocytic leukemia (CLL) and that CLL progression but not Richter’s...

gynecologic cancers
gynecologic cancers

Complex Surgery Does Not Independently Predict Outcome in Advanced Ovarian Cancer

In an analysis in the Gynecologic Oncology Group (GOG 182) trial population reported in the Journal of Clinical Oncology, Horowitz et al found that more complex surgery was not an independent predictor of progression-free or overall survival among patients with advanced epithelial ovarian or...

gynecologic cancers

Oral Bisphosphonate Use Reduces Risk of Postmenopausal Endometrial Cancer

Bisphosphonate use for treatment or prevention of osteoporosis in postmenopausal women has been associated with a reduced risk of breast cancer, including in a study in the Women’s Health Initiative (WHI) population. In a WHI study reported in the Journal of Clinical Oncology, Newcomb et al...

New Model Provides Improved Prediction of Breast Cancer Risk in African American Women

Breast cancer risk prediction models have underestimated the risk for African American women, a factor that has contributed to lower rates of recruitment to prevention trials in this population. In a study reported in the Journal of Clinical Oncology, Boggs et al developed a risk model, derived...

head and neck cancer

Improved TNM Prediction of Survival in HPV‑Related Oropharyngeal Carcinoma

In a study reported in the Journal of Clinical Oncology, Huang et al showed that recursive portioning analysis (RPA) could be used to provide TNM stage grouping with improved prediction of survival in patients with human papillomavirus (HPV)-related nonmetastatic oropharyngeal carcinoma. ...

prostate cancer

Genomic Classifier Score Identifies Risk of Metastasis and Benefit of Adjuvant Radiotherapy After Radical Prostatectomy

In a study reported in the Journal of Clinical Oncology, Den et al found that a 22-biomarker genomic classifier score was predictive of a greater risk of metastasis and benefit of adjuvant vs salvage radiotherapy after radical prostatectomy for prostate cancer. Metastasis Risk The study involved...

issues in oncology

TP53 Mutations Common in Pediatric Adrenocortical Carcinoma

In a Children’s Oncology Group study reported in the Journal of Clinical Oncology, Wasserman et al found that germline TP53 mutations are common in children with adrenocortical carcinoma, with mutations encoding proteins with greater loss of function being at increased risk of multiple...

pancreatic cancer

Reduced Use of Radiotherapy for Unresectable Pancreatic Adenocarcinoma in the United States

In a study reported in a research letter in JAMA Surgery, Shapiro et al found that use of radiotherapy in unresectable pancreas cancer has decreased over time and that disparities in use can be identified. Decreasing Use The study involved Surveillance, Epidemiology, and End Results (SEER) data...

lymphoma

European Trial Indicates That Neither Dacarbazine Nor Bleomycin Should Be Omitted From ABVD Regimen for Early-Stage Favorable Hodgkin Lymphoma

In a European open-label noninferiority trial (German Hodgkin Study Group [GHSG)] HD13) reported in The Lancet, Behringer et al found poorer outcomes with omission of dacarbazine or bleomycin from treatment with ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) in patients with...

issues in oncology

Age-Related Clonal Hematopoiesis Associated With Increased Risk of All-Cause Mortality, Heart Disease, and Stroke, as Well as Blood Cancer

In a study reported in The New England Journal of Medicine, Jaiswal et al found somatic mutations associated with hematologic cancers at increasing frequency with increasing age, with presence of the mutations being associated with increased risk of hematologic cancers, all-cause mortality,...

colorectal cancer
issues in oncology

Genetic Diagnosis by Exome Sequencing Feasible for Familial Colorectal Cancer

In a study reported in the Journal of Clinical Oncology, Chubb et al found that genetic diagnosis of high-penetrance susceptibility to colorectal cancer can be achieved in a sizeable proportion of familial colorectal cancer cases via exome sequencing for germline mutations. Study Details The...

survivorship

Poor Health Status More Common Among Childhood Cancer Survivors vs Siblings, With Age‑Related Increase in Prevalence

In a study in the Childhood Cancer Survivor Cohort reported in the Journal of Clinical Oncology, Hudson et al found that poor health status was more common in survivors than in siblings, with an age-related increase in prevalence particularly evident in female survivors. In the study, 22,568...

lung cancer

Addition of Linifanib to Carboplatin-Paclitaxel Increases Progression-Free Survival and Toxicity in Advanced Nonsquamous NSCLC

In a phase II trial reported in Journal of Clinical Oncology, Ramalingam et al found that the addition of the VEGFR and PDGFR inhibitor linifanib to carboplatin-paclitaxel increased progression-free survival in patients with advanced nonsquamous non–small cell lung cancer (NSCLC). The...

breast cancer

Low Sentinel Node Biopsy False-Negative Rate With Immunohistochemistry After Neoadjuvant Chemotherapy in Biopsy-Proven Node-Positive Breast Cancer

In the phase II SN FNAC (Sentinel Node Biopsy Following Neoadjuvant Chemotherapy) trial, reported in the Journal of Clinical Oncology, Boileau et al found a sentinel node biopsy false-negative rate of 8.4% with mandatory use of immunohistochemistry and a sentinel node biopsy identification rate of...

gynecologic cancers
solid tumors

Revised Risk Classification for Pediatric Extracranial Germ Cell Tumors

In a study reported in the Journal of Clinical Oncology, Frazier et al used data from U.S. and UK clinical trials to identify a high-risk group of patients with pediatric extracranial germ cell tumors. Study Details The study involved data from seven germ cell tumor trials conducted by the...

leukemia

Bispecific CD19-Directed CD3 T-Cell Engager Blinatumomab Active in Adults With Relapsed/Refractory B-Cell Precursor ALL

In a phase II study reported in The Lancet Oncology, Topp et al found that the bispecific CD19-directed CD3 T-cell engager (BiTE) blinatumomab (Blincyto) was highly active in adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Blinatumomab binds to CD19 expressed ...

breast cancer

Worse Anxiety/Depression Symptoms in Patients Adopting ‘Helper’ Role in Breast Cancer Internet Support Group

In a study reported in the Journal of Clinical Oncology, Lepore et al found that patients assigned a helper role in a breast cancer Internet support group had worse anxiety/depression symptoms after completion of the intervention than those not assigned a helper role. Study Details In the study,...

colorectal cancer

No Survival Difference for Adjuvant Capecitabine vs 5-FU With or Without Oxaliplatin in Stage III Colon Cancer

In an analysis reported in The Lancet Oncology, Schmoll et al found no difference in survival outcomes with adjuvant capecitabine vs fluorouracil (5-FU)/leucovorin with or without oxaliplatin in patients with stage III colon cancer and no adverse impact of adjuvant oxaliplatin on post-relapse...

lymphoma

PD-1 Blockade With Nivolumab Produces High Response Rate in Relapsed/Refractory Hodgkin Lymphoma

Anti–PD-1 antibodies have been shown to be effective in solid tumors. There is evidence that the malignant Reed-Sternberg cells in Hodgkin lymphomas use the PD-1 pathway to evade immune detection, with alterations in chromosome 9p24.1 increasing levels of PD-L1 and PD-L2 and promoting...

cns cancers
issues in oncology

Germline SUFU Mutations Cause Gorlin Syndrome and Increase Risk for Childhood Medulloblastoma

In a study to identify causative mutations in patients with Gorlin syndrome without PTCH1 mutations, Smith et al found that germline mutations in SUFU were associated with Gorlin syndrome and with increased likelihood of Gorlin syndrome–associated childhood medulloblastoma. The study is...

issues in oncology

Cigarette Smoking Associated With Changes in Inflammation Markers

In a study reported in the Journal of the National Cancer Institute, Shiels et al found significant changes in levels of inflammatory/immune markers in current cigarette smokers vs nonsmokers. There was a significant relationship between time since quitting and return to nonsmoker levels for...

skin cancer

Telomere Length Genes Are Associated With Melanoma Risk

Longer telomeres have been associated with increased risk of melanoma. In a GenoMEL Consortium genome-wide association study reported in the Journal of the National Cancer Institute, Iles et al found that several single-nucleotide polymorphisms (SNPs) previously associated with leukocyte telomere...

leukemia

Anti-CD19 Bispecific T Cell Engager Blinatumomab Shows Activity in Relapsed/Refractory B-Precursor ALL

In a phase II study reported in the Journal of Clinical Oncology, Topp et al found that the bispecific T-cell engager (BiTE) antibody blinatumomab produced a high response rate in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL). BiTEs induce a transient cytolytic ...

issues in oncology

Cigarette Smoking Before Diagnosis of First Cancer Is Associated With Increased Risk of Second Cancers

In a study reported in the Journal of Clinical Oncology, Shiels et al found that prediagnostic smoking among survivors of stage I lung cancer or bladder, kidney, or head/neck cancer was associated with increased risk of second lung, bladder, kidney, and head and neck cancer. Study Details The...

issues in oncology
survivorship

Advanced-Practice Nurse Telephone Counseling Improves Rate of Cardiomyopathy Screening in At‑Risk Adult Survivors of Pediatric Cancer

In the ECHOS trial reported in the Journal of Clinical Oncology, Hudson et al found that the addition of two tailored telephone counseling sessions by an advanced-practice nurse to a mailed personalized survivorship care plan including cardiac screening recommendations resulted in a greater than...

solid tumors
bladder cancer

RTOG Pooled Analysis Shows Good Long-Term Outcomes After Bladder-Preserving Combined-Modality Therapy for Muscle-Invasive Bladder Cancer

In a pooled analysis of prospective Radiation Therapy Oncology Group (RTOG) studies reported in the Journal of Clinical Oncology, Mak et al found good long-term outcomes with bladder-preserving combined-modality therapy for muscle-invasive bladder cancer. Study Details The analysis included 468...

Proton Radiotherapy Safe and Effective in Pediatric Rhabdomyosarcoma

In a phase II study reported in the Journal of Clinical Oncology, Ladra et al found that proton radiotherapy was a safe and effective treatment in pediatric rhabdomyosarcoma. Proton radiotherapy can substantially reduce radiotherapy doses to normal tissue compared with conventional photon...

skin cancer

Briefer Biochemotherapy Yields Better Relapse-Free Survival but Greater Toxicity vs 1-Year High-Dose Interferon in High-Risk Melanoma

In a phase III trial (Southwest Oncology Group Intergroup S0008) reported in the Journal of Clinical Oncology, Flaherty et al found that a shorter course of biochemotherapy consisting of cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b produced better relapse-free...

lymphoma

Early Response to Dose-Intensive Chemotherapy Can Be Used to Tailor Subsequent Therapy in Pediatric Intermediate-Risk Hodgkin Lymphoma

As reported in the Journal of Clinical Oncology by Friedman and colleagues, the Children’s Oncology Group study AHOD0031 has shown that early response to dose-intensive chemotherapy can be used to tailor subsequent therapy in pediatric intermediate-risk Hodgkin lymphoma. Study Details In...

colorectal cancer
issues in oncology

Wide Geographic Variation in Use of Laparoscopic Colectomy for Colon Cancer

There has been a dramatic increase in the use of laparoscopic colectomy for colon cancer. In a Medicare data study reported in the Journal of Clinical Oncology, Reames and colleagues found that use of laparoscopic colectomy varied from 0% to 66.8% across hospital referral regions in the United...

sarcoma

Shorter-Duration Therapy Including Lower-Dose Cyclophosphamide Preserves Efficacy in Newly Diagnosed Low-Risk Rhabdomyosarcoma

Intergroup Rhabdomyosarcoma Study Group (IRSG) studies have shown improved failure-free survival with VAC (vincristine, dactinomycin, and cyclophosphamide) given with a total cumulative cyclophosphamide dose of 26.4 g/m2 compared with VA (vincristine and dactinomycin) in patients with subset 1...

survivorship

Scoring to Predict Individual Risk of Heart Failure Among Childhood Cancer Survivors

In a study reported in the Journal of Clinical Oncology, Chow and colleagues developed risk scoring that can identify likelihood of heart failure among childhood cancer survivors. Study Details The study involved survivors in the Childhood Cancer Survivor Study (CCSS) free of significant...

breast cancer

Language and Communication Cognitive Complaints Worsen After Initiation of Endocrine Therapy in Early-Stage Breast Cancer

Data suggest that cancer treatment puts patients at risk of cognitive impairment and that many patients exhibit impairment prior to treatment. In an observational cohort study reported in the Journal of Clinical Oncology, Ganz et al found that language and communication cognitive complaints were...

colorectal cancer

Increased Prediagnosis BMI Associated With Increased Risk of Second Obesity-Associated Cancers in Colorectal Cancer Survivors

Overweight and obesity are associated with increased risk of primary colorectal cancer, as well as increased risk of breast, endometrial, esophageal, pancreatic, and kidney cancers. In a pooled analysis of prospective cohort studies reported in the Journal of Clinical Oncology, Gibson et al found...

lung cancer

No Progression-Free Survival Benefit of Dacomitinib vs Erlotinib Overall or in KRAS Wild-Type Disease in Pretreated Advanced NSCLC

In a phase III ARCHER 1009 trial reported in The Lancet Oncology, Ramalingam et al found no progression-free survival benefit of the irreversible pan-HER tyrosine kinase inhibitor dacomitinib vs erlotinib among all patients with pretreated non–small cell lung cancer (NSCLC) or among those...

survivorship

Higher Alkylating Agent Exposure Associated With Impaired Spermatogenesis in Adult Survivors of Childhood Cancer

In a study in the St. Jude Lifetime Cohort Study population reported in The Lancet Oncology, Green et al found that increasing alkylating agent exposure was associated with impaired spermatogenesis in adult male survivors of childhood cancer who did not undergo radiation therapy as part of their...

leukemia

CD19-Directed CAR T Cells Produce Sustained Remission in Relapsed/Refractory ALL

In a study reported in The New England Journal of Medicine, Maude et al reported achieving sustained remissions in children and adults with relapsed/refractory acute lymphoblastic leukemia (ALL) using autologous CD19-targeted chimeric antigen receptor (CAR)-modified T cells. Study Details In the...

breast cancer

Second-Line Bevacizumab/Chemotherapy Improves Progression-Free Survival in Advanced HER2-Negative Breast Cancer

In the phase III TANIA trial reported in The Lancet Oncology, von Minckwitz et al found that adding bevacizumab (Avastin) to chemotherapy in second-line treatment improved progression-free survival after first-line bevacizumab plus chemotherapy in patients with HER2-negative locally recurrent or...

gynecologic cancers

HPV 16/18 Vaccine Shows Protective Efficacy in Women Aged > 25 Years in 4-Year Interim Follow-up of VIVIANE Study

In the 4-year interim follow-up of the VIVIANE study reported in The Lancet by Skinner et al, the human papillomavirus (HPV) 16/18 AS04-adjuvanted vaccine was found to be protective against 6-month persistent infection or cervical intraepithelial neoplasia grade 1 or higher (CIN1+) associated with...

issues in oncology
prostate cancer

AR-V7 in Circulating Tumor Cells Associated With Resistance to Enzalutamide and Abiraterone in Prostate Cancer

The androgen receptor isoform encoded by splice variant 7 is constitutively active as a transcription factor, despite lacking the ligand-binding domain that is the target of enzalutamide (Xtandi) and abiraterone (Zytiga). In a study reported in The New England Journal of Medicine, Antonarakis et al ...

gynecologic cancers
gynecologic cancers

No Increased Risk of Ovarian Cancer With Perineal Powder Use

Perineal powder use has been associated with increased risk of ovarian cancer in case-control studies and with increased risk of serous invasive ovarian cancer in a cohort study. In a large cohort study reported in the Journal of the National Cancer Institute, Houghton et al found no significant...

multiple myeloma

Subclinical Peripheral Neuropathy Is Common in Treatment-Naive Multiple Myeloma Patients, Correlates With Decreased Fingertip Innervation Density

In a study reported in the Journal of Clinical Oncology, Kosturakis et al found that the majority of patients with multiple myeloma had subclinical peripheral neuropathy prior to chemotherapy and that deficits corresponded with decreased fingertip innervation density. Study Details In the study,...

multiple myeloma

Adding Pan-Deacetylase Inhibitor Panobinostat to Bortezomib and Dexamethasone Improves Progression-Free Survival in Relapsed Myeloma

In the phase III PANORAMA1 trial reported in The Lancet Oncology, San-Miguel and colleagues found that adding the pan-deacetylase inhibitor panobinostat to bortezomib (Velcade) and dexamethasone improved progression-free survival in patients with relapsed or relapsed and refractory multiple...

lung cancer

SMaRT Oncology-3 Trial Reports Collaborative Care Program Reduces Major Depression in Patients With Lung Cancer

In the SMaRT Oncology-3 study reported in The Lancet Oncology, Walker et al found that an integrated collaborative treatment program for depression (‘depression care for people with cancer’) was associated with significantly reduced severity of depression compared with usual care in...

Primary Site of Neuroblastoma Tied to Differences in Biologic, Clinical Characteristics, Including Survival

In a study reported in Journal of Clinical Oncology, Vo et al in the International Neuroblastoma Risk Group Project found significant differences in clinical and biologic features of neuroblastoma according to primary tumor site, including poorer survival for adrenal sites of primary disease and...

head and neck cancer

No Benefit of Adding Cetuximab to Cisplatin and Accelerated Radiotherapy in Stage III or IV Head and Neck Carcinoma

Use of cisplatin or cetuximab (Erbitux) with radiotherapy improves overall survival in stage III or IV head and neck carcinoma, and adding cetuximab to platinum therapy improves overall survival in metastatic disease. In the phase III Radiation Therapy Oncology Group (RTOG) 0522 trial reported in...

lymphoma

No Significant Difference in Time to Treatment Failure With Rituximab Retreatment vs Maintenance in Low-Tumor-Burden Follicular Lymphoma

Maintenance rituximab (Rituxan) has been shown to improve progression-free survival vs observation in low-tumor-burden follicular lymphoma. In the Eastern Cooperative Oncology Group (ECOG) E4402 Trial (RESORT), reported in the Journal of Clinical Oncology, Kahl et al found no significant difference ...

lymphoma

Adding Lenalidomide to R-CHOP Appears to Overcome Negative Prognostic Impact of the Non-Germinal Center B-Cell Phenotype in DLBCL

A phase II study reported in the Journal of Clinical Oncology by Nowakowski et al indicates that the addition of lenalidomide (Revlimid) to R-CHOP (rituximab [Rituxan] plus cyclophosphamide, doxorubicin, vincristine, and prednisone)—a regimen known as R2CHOP—overcomes the negative...

Advertisement

Advertisement




Advertisement